Escamilla-Gomez, VirginiaGarcia-Gutierrez, ValentinLopez-Corral, LuciaGarcia-Cadenas, IrenePerez-Martinez, AriadnaMarquez-Malaver, Francisco JCaballero-Velazquez, TeresaGonzalez-Sierra, Pedro AViguria-Alegria, Maria CParra-Salinas, Ingrid MCalderon-Cabrera, CristinaGonzalez-Vicent, MartaRodriguez-Torres, NancyParody-Porras, RocioFerra-Coll, ChristelleOrti, GuillermoValcarcel-Ferreiras, DavidDe-la-Camara-LLanza, RafaelMoles, PaulaVelazquez-Kennedy, KyraJoão-Mende, MariaCaballero-Barrigon, DoloresPerez, EstefaniaMartino-Bofarull, RodrigoSaavedra-Gerosa, SilvannaSierra, JorgePoch, MarcZudaire-Ripa, Maria TDiaz-Perez, Miguel AMolina-Angulo, BlancaSanchez-Ortega, IsabelSanz-Caballer, JaimeMontoro-Gomez, JuanEspigado-Tocino, IldefonsoPerez-Simon, Jose A2023-02-082023-02-082020-03Escamilla Gómez V, García-Gutiérrez V, López Corral L, García Cadenas I, Pérez Martínez A, Márquez Malaver FJ, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplant. 2020 Mar;55(3):641-648.http://hdl.handle.net/10668/14653Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Drug developmentMolecularly targeted therapyAcute DiseaseHematopoietic Stem Cell TransplantationPyrazolesChronic DiseaseGraft vs Host DiseaseHumansNitrilesPyrimidinesRetrospective Studiesresearch article31700138open accessEnfermedad crónicaSíndrome de bronquiolitis obliteranteEnfermedad injerto contra huéspedInducción de remisiónProtocolos de quimioterapia combinada antineoplásicaAnálisis de supervivenciaProgresión de la enfermedad10.1038/s41409-019-0731-x1476-5365PMC7051903https://www.nature.com/articles/s41409-019-0731-x.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051903/pdf